EU MDR & IVDR Transition: Key Deadlines for 2026

The EU MDR IVDR transition has moved from planning to execution. With four EUDAMED modules becoming mandatory from 28 May 2026 and risk class specific deadlines running through 2029, medical device and IVD manufacturers cannot afford to treat these as background items anymore.

2026 is becoming a critical enforcement year because regulators are shifting focus from transition allowances to active enforcement. Manufacturers that delayed remediation activities during the notified body capacity bottleneck now face overlapping obligations across certification, EUDAMED registration, PMS maturity, and supply continuity planning. 

The EU MDR (2017/745) replaced the Medical Device Directive (MDD) and the In Vitro Diagnostic Directive (IVDD) with IVDR (2017/746). Both regulations introduced stricter clinical evidence requirements, mandatory post market surveillance, and registration obligations through EUDAMED. Legacy device deadlines under MDR are 2027 and 2028. Under IVDR, they run to 2027, 2028, or 2029, depending on device class. 

What Changed from MDD to MDR 

The MDD allowed member states to apply requirements differently through national law. MDR changed that. It applies directly and uniformly across the EU, which removed the flexibility manufacturers had previously relied on. 

Key changes under MDD to MDR compliance: 

1. Stronger clinical evidence requirements. Equivalence claims are harder to justify and require more supporting documentation.
2. Active post-market clinical follow-up (PMCF) and post-market surveillance (PMS) plans are now mandatory.
3. A Person Responsible for Regulatory Compliance (PRRC) must be appointed within each manufacturer organization.
4. EUDAMED registration is required for all manufacturers, importers, and authorized representatives.
5. Periodic Safety Update Reports (PSURs) are required for Class IIa, IIb, and III devices with ongoing updates throughout the device lifecycle. 

What Changed from IVDD to IVDR 

The IVDD to IVDR shift is more disruptive for IVD manufacturers than the MDR transition was for many device manufacturers. Under the IVDD, around 80% of IVDs were self-certified with no notified body involvement. Under the IVDR, a new four-tier classification system (Class A through D) reclassified many of those devices into categories that now require notified body assessment. 

Other major changes: 

1. Performance evaluation reports (PERs) are now mandatory for all IVDs.
2. Post-market performance follow-up (PMPF) and vigilance reporting apply from the date IVDR became applicable.
3. IVDR-compliant QMS under Article 10(8) was required for all legacy device manufacturers by 26 May 2025.
4. Cybersecurity documentation, vulnerability management, and secure software lifecycle evidence are increasingly reviewed during MDR and IVDR assessments, particularly for connected devices and SaMD products. 

MDR Transition Timelines:

1. Class III custom-made implantable devices: deadline was 26 May 2026. These must already be MDR certified.
2. Class III and most Class IIb implantable devices: 31 December 2027.
3. Class IIb (non-implantable), Class IIa, Class Is/Im: 31 December 2028.
4. Legacy devices can only continue MDR Article 120 if certain conditions are maintained. 

The European Commission published a simplification package (COM 2025/1023) in December 2025 that proposes changes to MDR and IVDR. This is still a legislative proposal and has not been adopted. Current rules remain in effect. Plan your 2026 compliance around the existing regulation, not the proposal. 

Manufacturers should also monitor new and updated MDCG guidance documents, particularly those related to legacy device conditions, notified body application expectations, PMCF/PMPF activities, and EUDAMED actor obligations, as these documents are increasingly being used by notified bodies during conformity assessments. 

Business Risk Beyond Compliance 

Missing MDR or IVDR transition deadlines does not only create regulatory risk. Manufacturers may face product withdrawal, interrupted EU distribution, loss of distributor agreements, delayed procurement approvals, and significant revenue disruption if certificates expire before transition activities are completed. 

IVDR Transition Timelines by Device Class 

1. Class D (e.g., HIV and hepatitis tests): NB application was due by 26 May 2025. The final market deadline is 31 December 2027.
2. Class C (e.g., cancer tests): NB application due by 26 May 2026. Written agreement due by 26 September 2026. Final deadline: 31 December 2028.
3. Class B and Class A sterile: NB application due by 26 May 2027. Written agreement due by 26 September 2027. Final deadline: 31 December 2029.
4. Class A non-sterile: No transition period. Full IVDR compliance was required from 26 May 2022. 

If you manufacture Class C IVDs, the notified body application deadline of 26 May 2026 is a few weeks away. If that application is not already in progress, it needs to be the immediate priority. 

EUDAMED Becomes Mandatory on 28 May 2026. 

On 27 November 2025, the European Commission confirmed that four EUDAMED modules are fully functional. Starting 28 May 2026, use of these modules is mandatory: 

1. Actor Registration, including the Single Registration Number (SRN)
2. UDI/Device Registration
3. Notified Bodies and Certificates
4. Market Surveillance 

EUDAMED registration applies regardless of where your device sits in its transition timeline. A legacy IVD still operating under IVDR transition provisions must still be registered in EUDAMED by the 2026 deadline. 

The remaining EUDAMED modules, including Vigilance and Clinical Investigations/Performance Studies, are not yet mandatory but may become mandatory in later implementation phases.

What Manufacturers Need to Do Now